BridgeBio Stock Surges Following AstraZeneca and Ionis' Failed Heart Drug Trial
BridgeBio's stock surged after a rival heart drug, developed by AstraZeneca and Ionis Pharmaceuticals, failed to meet its primary endpoint in a late-stage trial for ATTR-CM. The failure shifted investor attention toward BridgeBio’s approved treatment for the same condition.
Topics: ATTR-CM biotech competition drug failure stock movement